The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumabYingcai Feng,Yuan Hong,Hanzi Sun,Bo Zhang,Hongfu Wu,Kang Li,Xuesong (Mike) Liu,Ye LiuCANCER RESEARCH(2019)引用 21|浏览10暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要